Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas A Rubinson

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Hematology/Oncology Clinics of North America|October 20, 2022
PrefaceDouglas A Rubinson, Matthew B Yurgelun
Hematology/Oncology Clinics of North America|August 1, 2015
Therapeutic Approaches for Metastatic Pancreatic AdenocarcinomaDouglas A Rubinson, Brian M Wolpin
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 5, 2022
The past, present, and future of chemotherapy with a focus on individualization of drug dosingLouis DeRidder, Douglas A Rubinson, Robert Langer, et al.
The EMBO Journal|December 6, 2003
A La protein requirement for efficient pre-tRNA foldingGhadiyaram Chakshusmathi, Sang Do Kim, Douglas A Rubinson, et al.
Current Biology : CB|January 31, 2002
ARF is not required for apoptosis in Rb mutant mouse embryosKenneth Y Tsai, David MacPherson, Douglas A Rubinson, et al.
Journal of Neurology|February 27, 2021
Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumabMahsa Khayat-Khoei, Sarah Conway, Douglas A Rubinson, et al.
Annual Review of Physiology|February 16, 2005
Rnai as an experimental and therapeutic tool to study and regulate physiological and disease processesChristopher P Dillon, Peter Sandy, Alessio Nencioni, et al.
JCO Oncology Practice|June 12, 2025
Clinical Implications of a Large-Scale Voluntary Preemptive <i>DPYD</i> Testing Program for Patients Planned for a Systemic Fluoropyrimidine: Preliminary ResultsLucy Yu, Jennifer Espiritu, Krishna Patel, et al.
Molecular Biology of the Cell|July 23, 2002
Critical roles of phosphorylation and actin binding motifs, but not the central proline-rich region, for Ena/vasodilator-stimulated phosphoprotein (VASP) function during cell migrationJoseph J Loureiro, Douglas A Rubinson, James E Bear, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 18, 2002
ARF mutation accelerates pituitary tumor development in Rb+/- miceKenneth Y Tsai, David MacPherson, Douglas A Rubinson, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Hematology/Oncology Clinics of North America|October 20, 2022
PrefaceDouglas A Rubinson, Matthew B Yurgelun
Hematology/Oncology Clinics of North America|August 1, 2015
Therapeutic Approaches for Metastatic Pancreatic AdenocarcinomaDouglas A Rubinson, Brian M Wolpin
Journal of Controlled Release : Official Journal of the Controlled Release Society|November 5, 2022
The past, present, and future of chemotherapy with a focus on individualization of drug dosingLouis DeRidder, Douglas A Rubinson, Robert Langer, et al.
The EMBO Journal|December 6, 2003
A La protein requirement for efficient pre-tRNA foldingGhadiyaram Chakshusmathi, Sang Do Kim, Douglas A Rubinson, et al.
Current Biology : CB|January 31, 2002
ARF is not required for apoptosis in Rb mutant mouse embryosKenneth Y Tsai, David MacPherson, Douglas A Rubinson, et al.
Journal of Neurology|February 27, 2021
Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumabMahsa Khayat-Khoei, Sarah Conway, Douglas A Rubinson, et al.
Annual Review of Physiology|February 16, 2005
Rnai as an experimental and therapeutic tool to study and regulate physiological and disease processesChristopher P Dillon, Peter Sandy, Alessio Nencioni, et al.
JCO Oncology Practice|June 12, 2025
Clinical Implications of a Large-Scale Voluntary Preemptive <i>DPYD</i> Testing Program for Patients Planned for a Systemic Fluoropyrimidine: Preliminary ResultsLucy Yu, Jennifer Espiritu, Krishna Patel, et al.
Molecular Biology of the Cell|July 23, 2002
Critical roles of phosphorylation and actin binding motifs, but not the central proline-rich region, for Ena/vasodilator-stimulated phosphoprotein (VASP) function during cell migrationJoseph J Loureiro, Douglas A Rubinson, James E Bear, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 18, 2002
ARF mutation accelerates pituitary tumor development in Rb+/- miceKenneth Y Tsai, David MacPherson, Douglas A Rubinson, et al.
Pageof 7